System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Roberto Cairoli is an expert in Hematology at Ospedale Niguarda Ca' Granda (Italy). As of October 2026, ScienceLeadR ranks Roberto Cairoli in the top 1% of experts worldwide for Leukemia. Roberto Cairoli has authored 268 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 5 of them ongoing. SLR score: 1,240 (community average: 125). How the SLR is computed.

LeadR Profile

Roberto Cairoli Ospedale Niguarda Ca' Granda Italy
1 240 ScienceLeadR Reputation 1240

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Transplantation - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Ospedale Niguarda Ca' Granda

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 268

Citations

Citations: 5 090 1st author: 24 Last author: 68 Unique author: 0

Main journals

Blood 86
Am J Hematol 13
Haematologica 12
Hematol Oncol 11
Hemasphere 9

Best Journals

J Clin Oncol 2
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The Germline SH2B3 rs111340708 Splicing Variant Drives Intron Retention and Protein Instability by Impacting Clinical Outcomes in Core Binding Factor AML.
PMID 42731102 — cells, genes, hematology, core binding factors, leukemia, introns, medical oncology, retention, psychology		Hematol Oncol20260
Association analysis between HLA evolutionary divergence and CMV serological status in a cohort of 526 adult subjects.
PMID 42624171 — transplantation immunology		Transpl Immunol20260
DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.
PMID 42559007		EJHaem20260
A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.
PMID 41827706 — research design, leukemia, myeloid, acute, transplants, therapeutics		Cancers (Basel)20260
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.
PMID 41733942 — mortality, drug therapy, therapeutics, chemotherapy		Blood Adv20260

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 8
Phase 2 6
N/A 2

By status:

Recruiting 7
Completed 2
Not yet recruiting 2
Terminated 2
Unknown 2
Active not recruiting 1

By type:

Interventional 14
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 15

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate the effect of adding bleximenib to standard of care treatment with intensive chemotherapy in patients with a specific type of acute myeloid leukemia (AML)
2025-522767-15-00 — leukemia, drug therapy, leukemia, myeloid, acute, maintenance, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2026
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy
2024-512753-24-00 — genes, leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2025
A Study of Bleximenib Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia
2024-520154-38-00 — leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Recruiting2025
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1 Mutated AML or MDS AML Considered Ineligible for Intensive Chemotherapy
NCT07075016 — leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Recruiting2025
Revumenib in Combination With Azacitidine Venetoclax in Patients NPM1 mutated or KMT2A rearranged AML
NCT06652438 — cells, genes, leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, mutation, chemotherapy		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS